RT Journal Article
SR Electronic
T1 A randomized, placebo-controlled trial of a nasal spray solution containing broadly potent neutralizing antibodies against SARS-CoV-2 variants in healthy volunteers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.04.22280574
DO 10.1101/2022.10.04.22280574
A1 Imsuwansri, Thanarath
A1 Jongthitinon, Thitinan
A1 Pojdoung, Niramon
A1 Meesiripan, Nuntana
A1 Sakarin, Siriwan
A1 Boonkrai, Chatikorn
A1 Wongtangprasert, Tossapon
A1 Phakham, Tanapati
A1 Audomsun, Thittaya
A1 Attakitbancha, Chadaporn
A1 Saelao, Pijitra
A1 Muanwien, Phijitra
A1 Tian, Maoxin Tim
A1 Tongchusak, Songsak
A1 Sangruji, Bhrus
A1 Wannigama, Dhammika Leshan
A1 Sawangmake, Chenphop
A1 Rodprasert, Watchareewan
A1 Le, Quynh Dang
A1 Purbantoro, Steven Dwi
A1 Vasuntrarak, Kananuch
A1 Nantavisai, Sirirat
A1 Sirilak, Supakit
A1 Uppapong, Ballang
A1 Sapsutthipas, Sompong
A1 Trisiriwanich, Sakalin
A1 Somporn, Thitiporn
A1 Usoo, Asmah
A1 Mingngamsup, Natthakarn
A1 Phumiamorn, Supaporn
A1 Aumklad, Porawan
A1 Arunprasert, Kwanputtha
A1 Patrojanasophon, Prasopchai
A1 Opanasopit, Praneet
A1 Pesirikan, Norapath
A1 Nitisaporn, Ladda
A1 Pitchayakorn, Jesada
A1 Narkthong, Thana
A1 Mahong, Bancha
A1 Chaiyo, Kumchol
A1 Srisuthisamphan, Kanjana
A1 Viriyakitkosol, Ratchanont
A1 Aeumjaturapat, Songklot
A1 Jongkaewwattana, Anan
A1 Bunnag, Sakarn
A1 Pisitkun, Trairak
YR 2022
UL http://medrxiv.org/content/early/2022/10/05/2022.10.04.22280574.abstract
AB Successful COVID-19 prevention requires additional measures beyond vaccination, social distancing, and masking. A nasal spray solution containing human IgG1 antibodies against SARS-CoV-2 (COVITRAP™) was developed to strengthen other COVID-19 preventive arsenals. Here, we evaluated its pseudovirus neutralization potencies, preclinical and clinical safety profiles, and intranasal SARS-CoV-2 inhibitory effects in healthy volunteers (NCT05358873). COVITRAP™ exhibited broadly potent neutralizing activities against SARS-CoV-2 with PVNT50 values ranging from 0.0035 to 3.1997 μg/ml for the following variants of concern (ranked from lowest to highest): Alpha, Beta, Gamma, Ancestral, Delta, Omicron BA.1, Omicron BA.2, Omicron BA.4/5, and Omicron BA.2.75. It demonstrated satisfactory preclinical safety profiles based on evaluations of in vitro cytotoxicity, skin sensitization, intracutaneous reactivity, and systemic toxicity. Its intranasal administration in rats did not yield any detected circulatory levels of the human IgG1 anti-SARS-CoV-2 antibodies at any time point during the 120 hours of follow-up. A double-blind, randomized, placebo-controlled trial (RCT) was conducted on 36 healthy volunteers who received either COVITRAP™ or a normal saline nasal spray at a 3:1 ratio. Safety of the thrice-daily intranasal administration for 7 days was assessed using nasal sinuscopy, adverse event recording, and self-reporting questionnaires. COVITRAP™ was well tolerated, with no significant adverse effects in healthy volunteers for the entire 14 days of the study. The intranasal SARS-CoV-2 inhibitory effects of COVITRAP™ were evaluated in nasal fluids taken from volunteers pre- and post-administration using a SARS-CoV-2 surrogate virus neutralization test. SARS-CoV-2 inhibitory effects in nasal fluids collected immediately or six hours after COVITRAP™ application were significantly increased from baseline for all three variants tested, including Ancestral, Delta, and Omicron BA.2. In conclusion, COVITRAP™ was safe for intranasal use in humans to provide SARS-CoV-2 inhibitory effects in nasal fluids that lasted at least six hours. Therefore, COVITRAP™ can be considered an integral instrument for COVID-19 prevention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05358873Funding StatementThis study was sponsored by HIBIOCY Co., Ltd., and funded by the Program Management Unit Competitiveness (PMU-C) [Grant No. C10F650051], Ministry of Higher Education, Science, Research and Innovation, Thailand.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Department of Medical Services, Ministry of Public Health, Thailand gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.